Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) (NCT06445322)
Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
🩺 Plain-English Summary (8th-Grade Level)
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Who can join: Review the eligibility criteria below.
Location: University of San Francisco — San Francisco, California
Age range: 5 Years
🧪 Interventions in This Study
- Prescreening Assessments (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- University of San Francisco — San Francisco, California
- Vitreo Retinal Associates — Gainesville, Florida
- Wilmer Eye Institute at John Hopkins — Baltimore, Maryland
- Massachusetts Eye and Ear — Boston, Massachusetts
- University of Michigan Kellogg Eye Center — Ann Arbor, Michigan
- Cincinnati Eye Institute — Cincinnati, Ohio
- Retina Foundation of Texas — Dallas, Texas
- Retina Consultants of Texas — Houston, Texas
📞 Contact the Study Coordinator
Phone: (207) 573-0412
Email: researchtrials@ascidian-tx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Stargardt Disease
- An Observational Study in Children and Adults With Stargardt Disease — Dallas, Texas
- Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study — Miami, Florida
- Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) — Phoenix, Arizona
- A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease — Phoenix, Arizona
- Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease — Bakersfield, California
- Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) — San Francisco, California
Explore by condition: All Stargardt Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.